ARTICLE | Clinical News

University of Birmingham reports Phase I data for leukemia vaccine

March 2, 2018 5:20 PM UTC

Researchers at the University of Birmingham (Birmingham, U.K.) reported data from a Phase I trial in 9 healthy volunteers showing that escalating doses of leukemia candidate pDOM-HA-1 boosted with a modified vaccinia Ankara virus (MVA) were safe with no serious adverse events reported.

pDOM-HA-1 is vaccine against histocompatibility minor HA-1 (HMHA1; HA-1; HLA-HA1). The candidate is being developed as a pretreatment for lymphocyte donors before allogeneic stem cell transplant to treat leukemia. Vaccination of HA-1-negative donors before they donate could generate cytotoxic T lymphocyte (CTLs) that recognize HA-1 in patients whose leukemias express that antigen...